Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

129
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
129
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

10.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV.

Nature communications·2026
Same author

Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.

Cancers·2026
Same author

ApoE-Dependent Lipid Handling by Median Eminence Microglia Preserves Myelin Integrity and Metabolic Function.

bioRxiv : the preprint server for biology·2026
Same author

Osteoprotegerin-Enabled Immune Evasion of Pathological Adipose Stromal Cells Drives Metabolic Dysfunction in Obesity.

bioRxiv : the preprint server for biology·2026
Same author

Assessment of Large Language Models for Enhancing Diabetologist-Developed Personalized Treatment Plans in Complex Type 2 Diabetes.

Clinical diabetes : a publication of the American Diabetes Association·2025
Same author

An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.

Blood advances·2025
Same journal

From Chaos to Care: Personalized AI for Early Cardiac Arrhythmia Warning.

medRxiv : the preprint server for health sciences·2026
Same journal

Large distant deletion disrupts CDKN2A enhancer and predisposes to melanoma.

medRxiv : the preprint server for health sciences·2026
Same journal

Artificial Intelligence-Based Chatbots in Genetic Counseling Practice: Current Uptake, Utilization, and Perspectives.

medRxiv : the preprint server for health sciences·2026
Same journal

Longitudinal MAP-MRI-based Assessment of Tissue Microstructural Alterations in Acute mTBI.

medRxiv : the preprint server for health sciences·2026
Same journal

A class of deep intronic <i>IGHMBP2</i> variants activate a shared cryptic splice donor, enabling correction of select variants with a single antisense oligonucleotide.

medRxiv : the preprint server for health sciences·2026
Same journal

Global Socioeconomic Context and Brain Ageing in Epilepsy: an ENIGMA-Epilepsy study.

medRxiv : the preprint server for health sciences·2026
See all related articles

Related Experiment Video

Updated: May 15, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K

Real-World Type 2 Diabetes Second-Line Treatment Allocation Among Patients.

Jaysón Davidson1,2, Rohit Vashisht1,2, Kendra Radtke1

  • 1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA.

Medrxiv : the Preprint Server for Health Sciences
|April 8, 2025
PubMed
Summary
This summary is machine-generated.

Socioeconomic disparities significantly impact second-line type 2 diabetes (T2D) treatment selection, with lower-income patients more likely to receive less advanced therapies. Addressing these social determinants of health is crucial for equitable care.

Keywords:
Type 2 diabetesarea deprivation indexhealthcare disparitiessocial determinants of healthtreatment decision-making

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.7K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.0K

Related Experiment Videos

Last Updated: May 15, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.7K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.0K

Area of Science:

  • Endocrinology and Metabolism
  • Health Services Research
  • Health Equity

Background:

  • Socioeconomic disparities are prevalent in healthcare access and outcomes.
  • Understanding these disparities is critical for optimizing treatment strategies in chronic diseases like type 2 diabetes (T2D).

Purpose of the Study:

  • To evaluate how socioeconomic factors influence the choice of second-line T2D medications.
  • To identify specific social determinants of health (SDOH) associated with treatment allocation.

Main Methods:

  • An observational study analyzed real-world data of over 9 million T2D patients initiating second-line therapy.
  • Multinomial regression models assessed the association between socioeconomic status and medication choice.
  • GPT-4 analyzed clinical notes to identify adverse SDOH across multiple domains.

Main Results:

  • Patients from lower socioeconomic neighborhoods were more likely to receive sulfonylureas (SUs) compared to DPP4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors.
  • Adverse SDOH, including housing, transportation, and employment issues, were identified in clinical notes.
  • Specific odds ratios indicated a trend towards less advanced therapies for patients with lower socioeconomic status.

Conclusions:

  • Socioeconomic status is a significant determinant in selecting second-line T2D treatments.
  • Equitable access to advanced T2D therapies requires addressing identified socioeconomic disparities and SDOH.